“Global T-Cell Lymphoma Market & Clinical Pipeline Insight” Report Highlight: Mechanism of T-Cell Lymphoma Therapeutics T-Cell Lymphoma Drug Market Overview T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase T-Cell Lymphoma Drug Clinical Pipeline By Peripheral & Cutaneous T-cell Lymphoma T-Cell Lymphoma Drug Clinical Pipeline: 24 Drugs Orphan Designated T-Cell Lymphoma Drugs: 22 Drugs Marketed T Cell Lymphoma Drug Clinical Insight Marketed T Cell Lymphoma Drugs: 15 Drugs T-Cell Lymphoma Drug Market Future Prospects

1. Global T Cell Lymphoma Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com, +91-11-47067990 Page 1
Immune system consists of various cells that impart resistance to body against foreign
entities. They also prevent the development of aberrant cells in the body to maintain its
normal functioning. However, it has been noted that these cells are also liable for
deterioration leading to diseases development. For instance, T-cell lymphoma is cancer
causing unrestricted growth of T-cells leading to impaired immune system. Investigators have
identified different T-cell malignancies that cause high morbidity and mortality. As a result,
several cancer therapeutics have been developed in past years to prevent T-cell lymphoma
proliferation and progression.
T-cell lymphoma is divided into several disease segments based on their pathophysiology that
causes difficulty in identification and treatment. Most of the therapeutics have been
developed for the Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)
which affects blood and skin, respectively. Other subcategories of T-cell lymphoma are
largely untouched due to which large unmet necessities could be observed. For instance,
Adult T-cell lymphoma is found in 2%-5% patients suffering from Human T-Lymphotropic
Viruses, type I (HTLV-1) infection. Generally chemotherapeutics approaches are used which
have modest safety and efficacy profiles. As a result, appropriate therapeutics is not
available leading to high unmet medical necessities giving emphasis on development of
innovative modalities for T-cell lymphoma treatment.
With time, new modalities are expected to be developed as underlying principles behind T-
cell lymphoma would be deciphered. For instance, investigators developed extracorporeal
photopheresis as an advanced method that could improve survival in patients. Low toxicity
and activation of treatment on demand are among one of the most sought features. This
procedure could also be used with other therapeutics to achieve better pharmacological
effects. Despite these benefits, its utility is limited because of special procedure requiring
patients to stay in hospital for T-cell lymphoma treatment. This scenario indicates that more
research and development is required for new and improved T-cell lymphoma therapeutics.
Some of the progress has been made by developing immunotoxin, HDAC inhibitors,
monoclonal antibodies and other investigational therapeutics.
Technological advancements are expected to help the investigators to develop better
therapeutics and increase the discovery rates. Increased investments in research and
development are expected to help in development of better therapeutic with superior

2. Global T Cell Lymphoma Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com, +91-11-47067990 Page 2
pharmacological and commercialization potential. They are expected to offer severe
competition to existing therapeutics due to which more revenues are expected to be
generated. Lots of opportunity are available as myriad of candidates with different biological
properties are under T-cell lymphoma clinical trials. Cancer market is expected to witness
introduction of several innovative products which will help the pharmaceutical companies to
generate significant revenues. These products are at different stages of clinical trials due to
which they would take some time before entering in global market. In this way, future T-cell
lymphoma therapeutics looks optimistic due to their superior pharmacological profiles.
“Global T-Cell Lymphoma Market & Clinical Pipeline Insight” Report Highlight:
• Mechanism of T-Cell Lymphoma Therapeutics
• T-Cell Lymphoma Drug Market Overview
• T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase
• T-Cell Lymphoma Drug Clinical Pipeline By Peripheral & Cutaneous T-cell Lymphoma
• T-Cell Lymphoma Drug Clinical Pipeline: 24 Drugs
• Orphan Designated T-Cell Lymphoma Drugs: 22 Drugs
• Marketed T Cell Lymphoma Drug Clinical Insight
• Marketed T Cell Lymphoma Drugs: 15 Drugs
• T-Cell Lymphoma Drug Market Future Prospects
For Report Sample Contact: neeraj@kuickresearch.com

3. Global T Cell Lymphoma Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com, +91-11-47067990 Page 3
Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-I
6.5 Phase-I/II
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III
7. Marketed T-Cell Lymphoma Drug Clinical Insight
7.1 Belinostat (Beleodaq)
7.2 Denileukin Diftitox (ONTAK)
7.3 Mogamulizumab (Poteligeo)

4. Global T Cell Lymphoma Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com, +91-11-47067990 Page 4
7.4 Brentuximab Vedotin (Adcetris)
7.5 Pralatrexate (Difolta/Folotyn)
7.6 Interferon gamma 1a Biosimilar (Imunomax-γ)
7.7 Nelarabine (Arranon/ Atriance)
7.8 Vorinostat (Zolinza)
7.9 Romidepsin (Istodax)
7.10 Bexarotene Topical (Targretin Gel)
7.11 Bexarotene Oral (Targretin Oral)
7.12 Chlormethine (Ledaga/Valchlor
7.13 Methoxsalen Solution (UVADEX)
7.14 Mogamulizumab Companion Diagnostics (Poteligeo Test FCM/IHC)
7.15 Interferon alpha-2a (Roferon-A)
8. Discontinued & No Development Reported in T-Cell Lymphoma Drug in Clinical
Pipeline
8.1 Discontinued
8.2 No Development Reported
9. Competitive Landscape
9.1 Actelion Pharmaceuticals
9.2 Allos Therapeutics
9.3 Astellas Pharma
9.4 BioCryst Pharmaceuticals
9.5 Bristol-Myers Squibb
9.6 Chipscreen Biosciences
9.7 Celgene Corporation
9.8 Eisai

5. Global T Cell Lymphoma Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com, +91-11-47067990 Page 5
9.9 Genmab
9.10 Galderma
9.11 Inovio Pharmaceuticals
9.12 Johnson & Johnson Pharmaceutical Research & Development
9.13 Karyopharm Therapeutics
9.14 Kyowa Hakko Kirin
9.15 Nippon Kayaku
9.16 Novartis
9.17 Neumedicines
9.18 Onyx Pharmaceuticals
9.19 Roche
9.20 Seattle Genetics
9.21 Shionogi
9.22 Soligenix
9.23 TetraLogic Pharmaceuticals
9.24 ZIOPHARM Oncology

6. Global T Cell Lymphoma Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com, +91-11-47067990 Page 6
List of Figures
Figure 1-1: Main Types of Blood Cancer
Figure 1-2: Types of White Blood Cells (WBC)
Figure 1-3: Types of Lymphoma
Figure 1-4: Major Type of T-Cell Lymphoma
Figure 1-5: Type of Anaplastic Large Cell Lymphoma
Figure 1-6: Type of Uncommon T-Cell Lymphomas
Figure 2-1: Extracorporeal Photopheresis (ECPP)
Figure 2-2: Mechanism of Bexarotene
Figure 2-3: Mechanism of Pralatrexate
Figure 2-4: Mechanism of Vorinostat
Figure 2-5: Mechanism of Denileukin Diftitox
Figure 2-6: Mechanism of Romidepsin
Figure 2-7: Mechanism of Alemtuzumab
Figure 3-1: T-Cell Lymphoma Pipeline by Phase(%), 2016
Figure 3-2: T-Cell Lymphoma Pipeline by Phase(Numbers), 2016
Figure 3-3: T-Cell Lymphoma Pipeline by Phase (%), 2016
Figure 3-4: T-Cell Lymphoma Pipeline by Phase (Numbers), 2016
Figure 4-1: T-Cell Lymphoma Drug Market Favorable Parameters
Figure 4-1: T-Cell Lymphoma Drug Market Commercialization Challenges
Table 1-1: Staging of T-Cell Lymphoma
For Report Sample Contact: neeraj@kuickresearch.com

7. Global T Cell Lymphoma Market & Clinical Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com, +91-11-47067990 Page 7